(2S,6R,14S,15S,19S)-5-(cyclopropylmethyl)-19-(2-hydroxy-3,3-dimethylbutan-2-yl)-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11,16-tetraen-11-ol

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 吗啡烷
• 英文名称: (2S,6R,14S,15S,19S)-5-(cyclopropylmethyl)-19-(2-hydroxy-3,3-dimethylbutan-2-yl)-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11,16-tetraen-11-ol
• 化学式: C₂₉H₃₉NO₄
• 分子量: 465.6
• InChiKey: XXEUUFWMPBSHCE-BVHURTBRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  34
• 可旋转键数：
  5
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.72
• 拓扑面积：
  62.2
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• PAIN MANAGEMENT IN SICKLE CELL ANEMIA
  申请人：Regents of the University of Minnesota

  公开号：US20140171466A1

  公开（公告）日：2014-06-19

  The present invention relates to a method for the management of pain associated with sickle cell disease. In particular, the method comprises administering to a patient in need of such pain management a therapeutically effective amount of a nociceptin (NOP) receptor agonist or an NOP receptor agonist/mu opioid receptor (MOR) partial agonist.
• Oral Pharmaceutical Compositions of Buprenorphine and Another Opioid Receptor Agonist
  申请人：Relmada Therapeutics, Inc.

  公开号：US20160176890A1

  公开（公告）日：2016-06-23

  The present invention is directed to oral pharmaceutical compositions of buprenorphine and it pharmaceutically acceptable salts and the use thereof.